Activation of LXR-α can result in the development of hepatic steatosis, which is mediated by the hepatic lipogenic pathway, primarily through SREBP-1c, causing hepatic steatosis and hyperlipidemia. The gene discussed is SREBF1; the disease is Hepatic steatosis.